Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007993 | 1.00 | CNR1 (0.45) | CNR1BTKUSP30PIK3CDMAPK8 | |
| SCHEMBL16008854 | 0.90 | DNMT3A (0.46) | BTKUSP30PIK3CDNSD2 | |
| SCHEMBL16008856 | 0.90 | DNMT3A (0.46) | BTKUSP30PIK3CDNSD2 | |
| SCHEMBL16009139 | 0.84 | BTK (0.46) | CNR1BTKUSP30PIK3CDBRD4 | |
| SCHEMBL16009140 | 0.84 | BTK (0.46) | CNR1BTKUSP30PIK3CDBRD4 | |
| SCHEMBL16008800 | 0.83 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL16008799 | 0.83 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL16008070 | 0.82 | NSD2 (0.51) | CNR1BTKUSP30PIK3CDMAPK8 | |
| SCHEMBL16008071 | 0.82 | NSD2 (0.51) | CNR1BTKUSP30PIK3CDMAPK8 | |
| SCHEMBL19497127 | 0.82 | MEN1 (0.39) | CNR1USP30MAPK8ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-3235814-B1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20180015083-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9801872-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| EP-3235814-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-2970202-B1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA INC. | 2016-10-27 | — | — | US | disclosed |
| US-9402841-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | CNR1 989/4885BTK 1/4885USP30 2954/4885 |
| US-20180015083-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | CNR1 989/4885BTK 1/4885USP30 2954/4885 |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | CNR1 989/4885BTK 1/4885USP30 2954/4885 |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | CNR1 989/4885BTK 1/4885USP30 2954/4885 |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | BTK, LCK, TYK2 | CNR1 989/4885BTK 1/4885USP30 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.